Argus Upgrades Silk Road Medical (NASDAQ:SILK) to Buy

Silk Road Medical (NASDAQ:SILK – Get Free Report) was upgraded by research analysts at Argus from a “hold” rating to a “buy” rating in a research note issued on Thursday, Marketbeat Ratings reports. The firm presently has a $24.00 price target on the stock. Argus’ target price would suggest a potential upside of 46.34% from […]

Leave a Reply

Your email address will not be published.

Previous post Salem Media Group (NASDAQ:SALM) Coverage Initiated at StockNews.com
Next post QUALCOMM (NASDAQ:QCOM) Stock Rating Lowered by StockNews.com